Technical Trend Overview and Price Action
Venus Remedies Ltd (stock code 568580) closed at ₹786.80 on 19 Jan 2026, marking a 1.20% gain from the previous close of ₹777.50. The stock traded within a range of ₹745.00 to ₹816.35 during the day, demonstrating intraday volatility but maintaining an upward bias. The 52-week high stands at ₹848.90, while the 52-week low is ₹272.20, highlighting a substantial appreciation over the past year.
The technical trend has softened from a clear bullish stance to a mildly bullish one, signalling a potential consolidation phase or a pause in the strong upward momentum witnessed previously. This shift is important for traders and investors to note, as it may indicate a period of sideways movement or selective profit-taking before the next directional move.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) remains bullish on both weekly and monthly timeframes, underscoring sustained positive momentum in the medium to long term. The MACD line continues to stay above the signal line, suggesting that the underlying trend remains intact despite short-term fluctuations.
However, the Relative Strength Index (RSI) presents a contrasting picture. Both weekly and monthly RSI readings are bearish, indicating that the stock may be experiencing some weakening in momentum or entering an oversold condition on these timeframes. This divergence between MACD and RSI often signals a potential correction or consolidation, as the stock’s price momentum slows down after a strong rally.
Moving Averages and Bollinger Bands
Daily moving averages remain bullish, with the stock price trading above key averages such as the 50-day and 200-day moving averages. This alignment supports the notion that the medium-term trend is still positive and that the stock has strong technical support levels below the current price.
Bollinger Bands on weekly and monthly charts are also bullish, indicating that volatility remains elevated but within an upward trending channel. The price touching or nearing the upper band during intraday highs suggests buying interest, although it also warns of potential short-term overextension.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Additional Technical Indicators: KST, Dow Theory, and OBV
The Know Sure Thing (KST) indicator remains bullish on both weekly and monthly charts, reinforcing the positive momentum narrative. This indicator’s strength suggests that the stock’s price gains are supported by underlying momentum shifts, which can be a reliable signal for trend continuation.
Conversely, Dow Theory readings are mildly bearish on the weekly timeframe and show no clear trend on the monthly scale. This mixed signal implies some uncertainty among market participants regarding the sustainability of the current rally, possibly reflecting profit-taking or cautious positioning ahead of upcoming catalysts.
On-Balance Volume (OBV) is mildly bearish weekly and neutral monthly, indicating that volume trends are not strongly supporting the price advances in the short term. This divergence between price and volume can sometimes precede a correction or a period of consolidation.
Comparative Returns and Market Context
Venus Remedies has delivered exceptional returns relative to the broader market. Over the past year, the stock has surged by 162.92%, vastly outperforming the Sensex’s 8.47% gain. Over three and five years, the stock’s returns stand at 364.19% and 361.74%, respectively, compared to Sensex returns of 39.07% and 70.43%. The ten-year return of 650.76% dwarfs the Sensex’s 241.73%, underscoring the company’s strong growth trajectory and investor confidence.
Year-to-date, Venus Remedies has gained 2.58%, while the Sensex has declined by 1.94%, further highlighting the stock’s resilience amid broader market weakness. However, the one-month return shows a slight decline of 1.30%, in line with the Sensex’s 1.31% drop, reflecting recent market volatility and the technical momentum shift noted earlier.
Valuation and Market Capitalisation
The company holds a Market Cap Grade of 4, indicating a mid-sized market capitalisation within its sector. This positioning allows for growth potential while maintaining sufficient liquidity for institutional investors. The recent upgrade in the Mojo Grade from Buy to Strong Buy on 14 Jan 2026, with a current Mojo Score of 80.0, reflects improved confidence in the stock’s fundamentals and technical outlook.
Investment Implications and Outlook
Investors should note the mixed signals from technical indicators. The bullish MACD and moving averages suggest that the stock remains in an uptrend, but the bearish RSI and mild bearishness in Dow Theory and OBV point to caution. This combination often precedes a consolidation phase, where the stock may trade sideways or experience minor pullbacks before resuming its upward trajectory.
Given the stock’s strong historical returns and relative outperformance versus the Sensex, long-term investors may view current price levels as an opportunity to accumulate, especially if the stock finds support near its moving averages. Traders, however, should monitor momentum oscillators closely for signs of trend exhaustion or reversal.
Venus Remedies Ltd caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Summary
Venus Remedies Ltd’s technical landscape is characterised by a subtle shift from bullish to mildly bullish momentum, reflecting a complex balance between positive medium-term indicators and short-term cautionary signals. The stock’s strong historical performance and relative strength against the Sensex provide a solid foundation for continued investor interest. However, the mixed readings from RSI, Dow Theory, and OBV suggest that investors should remain vigilant for potential consolidation or minor corrections.
Overall, the upgrade to a Strong Buy Mojo Grade and a high Mojo Score of 80.0 reinforce the stock’s favourable outlook, particularly for investors with a medium to long-term horizon. Monitoring key technical levels and momentum indicators will be crucial in navigating the stock’s next phase of price action within the Pharmaceuticals & Biotechnology sector.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
